Switch theme
Sign up to access all valuation multiples
Jointown Pharmaceutical Group Co Ltd is engaged in the business of wholesaling drugs and medical devices. The company offers logistics and other value-added services and primarily serves medical institutions, wholesale enterprises, and retail pharmacies.
1999
n/a
LTM Revenue $21.7B
LTM EBITDA $717M
$3.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jointown Pharmaceutical has a last 12-month revenue of $21.7B and a last 12-month EBITDA of $717M.
In the most recent fiscal year, Jointown Pharmaceutical achieved revenue of $20.7B and an EBITDA of $700M.
Jointown Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jointown Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $20.7B | $21.2B | XXX | XXX | XXX |
| Gross Profit | $1.4B | $1.5B | XXX | XXX | XXX |
| Gross Margin | 7% | 7% | XXX | XXX | XXX |
| EBITDA | $700M | $694M | XXX | XXX | XXX |
| EBITDA Margin | 3% | 3% | XXX | XXX | XXX |
| Net Profit | $337M | $287M | XXX | XXX | XXX |
| Net Margin | 2% | 1% | XXX | XXX | XXX |
| Net Debt | $32.0M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Jointown Pharmaceutical's stock price is CNY 5 (or $1).
Jointown Pharmaceutical has current market cap of CNY 24.3B (or $3.3B), and EV of CNY 24.2B (or $3.3B).
See Jointown Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.3B | $3.3B | XXX | XXX | XXX | XXX | $0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Jointown Pharmaceutical has market cap of $3.3B and EV of $3.3B.
Jointown Pharmaceutical's trades at 0.2x LTM EV/Revenue multiple, and 4.6x LTM EBITDA.
Analysts estimate Jointown Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jointown Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.3B | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | 4.8x | XXX | XXX | XXX |
| P/E | 10.1x | XXX | XXX | XXX |
| P/E/Growth | 0.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJointown Pharmaceutical's NTM/LTM revenue growth is 8%
Jointown Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Jointown Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jointown Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jointown Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 11% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 5% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jointown Pharmaceutical acquired XXX companies to date.
Last acquisition by Jointown Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Jointown Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jointown Pharmaceutical founded? | Jointown Pharmaceutical was founded in 1999. |
| Where is Jointown Pharmaceutical headquartered? | Jointown Pharmaceutical is headquartered in China. |
| Is Jointown Pharmaceutical publicy listed? | Yes, Jointown Pharmaceutical is a public company listed on SHG. |
| What is the stock symbol of Jointown Pharmaceutical? | Jointown Pharmaceutical trades under 600998 ticker. |
| When did Jointown Pharmaceutical go public? | Jointown Pharmaceutical went public in 2010. |
| Who are competitors of Jointown Pharmaceutical? | Similar companies to Jointown Pharmaceutical include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of Jointown Pharmaceutical? | Jointown Pharmaceutical's current market cap is $3.3B |
| What is the current revenue of Jointown Pharmaceutical? | Jointown Pharmaceutical's last 12-month revenue is $21.7B. |
| What is the current EBITDA of Jointown Pharmaceutical? | Jointown Pharmaceutical's last 12-month EBITDA is $717M. |
| What is the current EV/Revenue multiple of Jointown Pharmaceutical? | Current revenue multiple of Jointown Pharmaceutical is 0.2x. |
| What is the current EV/EBITDA multiple of Jointown Pharmaceutical? | Current EBITDA multiple of Jointown Pharmaceutical is 4.6x. |
| What is the current revenue growth of Jointown Pharmaceutical? | Jointown Pharmaceutical revenue growth between 2023 and 2024 was 2%. |
| Is Jointown Pharmaceutical profitable? | Yes, Jointown Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
